Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schwabl

Showing results (291-300 of 318) with videos related to

Pageof 32
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Radiology|March 29, 2022
Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD StudyAnna K Luger, Thomas Sonnweber, Leonhard Gruber, et al.
Journal of Hepatology|December 21, 2016
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunctionPhilipp Schwabl, Eva Hambruch, Berit A Seeland, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2026
Stage-specific drivers of clinical progression in advanced chronic liver diseaseBenedikt Simbrunner, Georg Semmler, Marta Bofill Roig, et al.
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Scientific Reports|June 21, 2018
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic ratsPhilipp Schwabl, Ksenia Brusilovskaya, Paul Supper, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Respiratory Research|October 22, 2020
Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort studyThomas Sonnweber, Anna Boehm, Sabina Sahanic, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 20, 2026
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical OutcomesBenedikt Silvester Hofer, Thomas Perkmann, Ksenia Brusilovskaya, et al.
Pageof 32

Showing results (291-300 of 318) with videos related to

Sort By:
Pageof 32
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Radiology|March 29, 2022
Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD StudyAnna K Luger, Thomas Sonnweber, Leonhard Gruber, et al.
Journal of Hepatology|December 21, 2016
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunctionPhilipp Schwabl, Eva Hambruch, Berit A Seeland, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2026
Stage-specific drivers of clinical progression in advanced chronic liver diseaseBenedikt Simbrunner, Georg Semmler, Marta Bofill Roig, et al.
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Scientific Reports|June 21, 2018
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic ratsPhilipp Schwabl, Ksenia Brusilovskaya, Paul Supper, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Respiratory Research|October 22, 2020
Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort studyThomas Sonnweber, Anna Boehm, Sabina Sahanic, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 20, 2026
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical OutcomesBenedikt Silvester Hofer, Thomas Perkmann, Ksenia Brusilovskaya, et al.
Pageof 32